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http://dx.doi.org/10.1016/j.ccell.2015.09.009SUMMARYIn normal cells, p53 is activated by DNA damage checkpoint kinases to simultaneously control the G1/S and
G2/M cell cycle checkpoints through transcriptional induction of p21cip1 and Gadd45a. In p53-mutant tu-
mors, cell cycle checkpoints are rewired, leading to dependency on the p38/MK2 pathway to survive
DNA-damaging chemotherapy. Here we show that the RNA binding protein hnRNPA0 is the ‘‘successor’’
to p53 for checkpoint control. Like p53, hnRNPA0 is activated by a checkpoint kinase (MK2) and simulta-
neously controls both cell cycle checkpoints through distinct target mRNAs, but unlike p53, this is through
the post-transcriptional stabilization of p27Kip1 and Gadd45a mRNAs. This pathway drives cisplatin resis-
tance in lung cancer, demonstrating the importance of post-transcriptional RNA control to chemotherapy
response.INTRODUCTION
Cytotoxic chemotherapy is a mainstay of cancer treatment, yet
the molecular mechanisms that govern sensitivity or resistance
to these agents in different tumor types are incompletely under-
stood. Many of the most commonly used chemotherapeutic
drugs exert their effects by causing DNA damage, leading to
the activation of a complex signaling network that facilitates
cell cycle arrest and/or cell death. During tumor evolution, how-
ever, many, if not all tumors disrupt components of the DNA
damage response network (DDR) to escape oncogene-induced
senescence (Bartkova et al., 2006), ultimately contributing to
genomic instability. Cytotoxic anti-cancer chemotherapy works
in large part by exploiting these DDRdifferences between normalSignificance
Platinum-containing regimens are frontline DNA-damaging the
ular mechanisms that drive resistance to chemotherapy are in
with mutations in p53 (50%) are critically dependent on th
for resistance to chemotherapy. hnRNPA0 regulates both p27K
DNA repair and tolerance to chemotherapy. Analysis of hnRNP
activity of this pathway correlates with therapeutic response.
hnRNPA0 pathway may predict a sub-population of patients l
Caand tumor cells (Ciccia and Elledge, 2010; Jackson and Bartek,
2009). Some tumor types, such as testicular cancers, show a
>80% response rate to chemotherapy (Kelland, 2007). In others,
such as non-small cell lung cancer (NSCLC), however, only
30% of patients respond favorably to cytotoxic platinum-
based chemotherapy while the remaining 70% receive little
to no benefit and suffer from drug-related toxicity (Socinski,
2004). Hence, NSCLC is an ideal system to interrogate molecular
mechanisms of intrinsic drug resistance. Importantly, the identi-
fication of chemotherapy resistance mechanisms could, in
principle, both delineate new targets for pharmacological inter-
vention and identify those patients most likely to benefit from
specific therapeutic regimens while limiting the extent of toxicity
associated with non-selective administration.rapies for non-small cell lung cancer (NSCLC), yet themolec-
completely understood. Here we show that NSCLC tumors
e activity of a post-transcriptional MK2/hnRNPA0 pathway
ip1 and Gadd45a to enforce cell cycle checkpoints, allowing
A0-target mRNAs in patients with NSCLC demonstrates that
Thus, pre-screening of patients for the activity of the MK2/
ikely to benefit most from chemotherapy.
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Figure 1. A Focused Screen Implicates p27Kip1 as an hnRNPA0-Dependent G1/S Regulator
(A) H1299 cells were depleted of hnRNPA0 or Gadd45a and treated with 2 mM doxorubicin for 4 hr followed by the addition of 250 ng/ml nocodazole for a further
24 hr. Cells were fixed and stained with propidium iodide and analyzed by flow cytometry. Yellow, blue, and green arrows depict loss of the G1/S checkpoint in
hnRNPA0 knockdown cells but not in Gadd45a knockdown cells.
(B) Schematic representation of the known role of hnRNPA0 in the DNA damage response.
(C) Cells were treated with doxorubicin for 16 hr, mRNA levels of the indicated targets were determined by qRT-PCR, and the data represented as fold-change
versus control siRNA vehicle-treated cells.
(D) qRT-PCR analysis of H1299 cells, 16 hr post-doxorubicin treatment. Data are represented as fold change versus control siRNA vehicle-treated cells. Error
bars represent mean ± SEM, n = 3 experiments. *p < 0.05, ***p < 0.001.
(legend continued on next page)
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Loss or mutation of the tumor suppressor p53 occurs in
approximately 50% of all tumors (Cheok et al., 2011). We
recently demonstrated that p53-deficient cells and tumors
become dependent on the p38/MK2 pathway for survival in
response to topoisomerase inhibitors or platinum-based
compounds (Morandell et al., 2013; Reinhardt et al., 2007), two
classes of commonly used chemotherapeutic agents. Those ob-
servations suggested that pharmacological targeting of MK2, or
its downstream effectors, might promote greater clinical efficacy
of chemotherapy in p53-deficient tumors (Morandell et al., 2013;
Reinhardt et al., 2007). It is also possible that the activity of this
pathway could be used to predict the efficacy of chemotherapy.
However, measuring MK2 expression levels or activation status
as biomarkers of chemotherapy response is likely to be
hampered by difficulties in directly assaying MK2 activity in tu-
mor cells, as well as the presence of high levels of MK2 expres-
sion in tumor-infiltrating stromal cells such as macrophages
(Morandell et al., 2013). A thorough mechanistic understanding
of tumor-specific MK2 effectors, however, could provide novel
biomarkers that would facilitate the identification of subsets of
patients most likely to benefit from chemotherapy.
We recently found that MK2 post-transcriptionally controls the
G2/M checkpoint through the RNA binding protein (RNA-BP)
hnRNPA0 promoting Gadd45a mRNA stabilization and protein
production (Reinhardt et al., 2010, 2011). In addition to loss of
the G2/M checkpoint, MK2 depleted p53-null cells also lose
the DNA damage-induced G1/S checkpoint. The molecular
mechanism underlying this G1/S checkpoint bypass, the relative
contributions of different cell cycle checkpoints to chemo-
therapy sensitization, and the mechanistic basis for synthetic
lethality between the p53 and MK2 pathways in response to
DNA-damaging chemotherapy have remained elusive.
RESULTS
A Focused Screen Implicates p27Kip1 as an hnRNPA0-
Dependent G1/S Regulator
As shown in Figure 1A, in addition to regulating the G2/M check-
point, loss of hnRNPA0 results in a pronounced loss of the
DNA damage-induced G1/S checkpoint in p53-null H1299
NSCLC cells (see also Figure S1A). Depletion of Gadd45a,
the only known hnRNPA0-target mRNA involved in cell cycle
control (Reinhardt et al., 2010), however, failed to recapitulate
the effect of hnRNPA0 knockdown on the G1/S checkpoint (Fig-
ure 1A, compare orange, blue and green arrows; see also Fig-
ure S1A), indicating that hnRNPA0 must regulate the G1/S
checkpoint through a different target mRNA(s) (Figure 1B). To
identify putative hnRNPA0-target mRNAs that might control
the G1/S checkpoint in these p53-deficient H1299 cells, we
next performed a focused mRNA expression screen following
hnRNPA0 depletion, looking for altered regulation of mRNAs
whose protein products have been implicated in regulating the(E) Western blots of H1299 cells 16 hr post-doxorubicin treatment.
(F) H1299 cells were treated with doxorubicin for 16 hr followed by the addition of c
levels measured by immuno-blotting.
(G) H1299 cells were treated with doxorubicin for 16 hr followed by the addition of
by qRT-PCR.
See also Figure S1.
CaG1/S transition in different contexts (Figure 1C). Based on the
assumption that hnRNPA0 regulates the stability of its target
mRNAs, as has been shown for Gadd45a (Reinhardt et al.,
2010), and thus their mRNA levels, we measured the expression
of these G1/S regulators by qRT-PCR in cells depleted of
hnRNPA0 by RNAi in the presence or absence of doxorubicin-
induced DNA damage. Treatment of H1299 cells with doxoru-
bicin led to a number of changes in the mRNA levels of several
G1/S regulators; however, only one of these mRNAs, p27Kip1,
appeared to be regulated in an hnRNPA0-dependent manner
(Figure 1C). We confirmed this effect of hnRNPA0 on p27Kip1
mRNA induction using a second independent siRNA targeting
a second distinct sequence within hnRNPA0. This independent
siRNA efficiently depleted hnRNPA0 at both the mRNA (Fig-
ure 1D) and protein level (Figure 1E) and prevented the induction
of both p27Kip1 and Gadd45a mRNAs in response to DNA dam-
age (Figure 1D). Furthermore, the marked induction of p27Kip1
protein levels that we observed after doxorubicin treatment
was blunted by hnRNPA0 knockdown (Figure 1E). Together
these data indicate that a single RNA-binding protein, hnRNPA0,
regulates the DNA damage-induced G1/S checkpoint indepen-
dently of stabilizing Gadd45a and that this G1/S checkpoint
may instead be mediated by DNA damage-induced induction
of p27Kip1.
The most well-established mechanism for p27Kip1 regulation
occurs at the level of protein stability through the action of the
ubiquitin ligase Skp2 (Frescas and Pagano, 2008). To investigate
whether increased protein stability could account for the upregu-
lation of p27Kip1 protein after DNA damage (Figure 1E), we
measured p27Kip1 protein half-life after doxorubicin induced
DNA damage by blocking translation with cycloheximide (Fig-
ures 1F and S1B). Surprisingly, despite a 2- to 3-fold increase
in total p27Kip1 protein levels (Figure 1E), doxorubicin treatment
led to a slight decrease in p27Kip1 protein stability (Figures 1F
and S1B), indicating that the observed induction of p27Kip1
following DNA damage does not result from increased protein
stability. Since hnRNPA0 is known to regulate Gadd45a in a
DNA damage-dependent manner through stabilization of its
mRNA (Reinhardt et al., 2010), we hypothesized that the
increased p27Kip1 levels seen after DNA damage could be due
to a similar stabilization of p27Kip1 mRNA. To test this, we treated
H1299 cells with doxorubicin for 16 hr, then added actinomycin
D to the culture medium to prevent new transcription and
measured p27Kip1 mRNA decay by qRT-PCR. Doxorubicin treat-
ment led to a fourfold increase in the half-life of p27Kip1 mRNA
(Figure 1G), similar in magnitude to the observed increase in total
p27Kip1 mRNA levels (Figures 1C and 1D). Next, we set out to
examine whether the regulation of p27kip1 by hnRNPA0 is medi-
ated by direct binding. In vitro binding experiments with a frag-
ment of the p27kip1 30 UTR harboring putative hnRNPA0 binding
sites (Figure S1C) (Wang et al., 2013) and the purified recombi-
nant hnRNPA0 RNA recognition motifs (RRMs) (Figures S1Dycloheximide. Samples were taken at indicated time points and p27Kip1 protein
actinomycin D. At indicated time points, p27Kip1 mRNA levels were determined
ncer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc. 625
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Figure 2. p27Kip1 Controls the DNA Damage-Induced G1/S Checkpoint in p53-Deficient Cells
(A) Western blots of H1299 cells transfected with p27Kip1-specific siRNA or infected with a miR-30-based retroviral p27Kip1-specific shRNA (shRNA#1).
(B) Representative flow cytometry profiles of propidium iodide-stained H1299 cells transfected with a control siRNA or a p27Kip1-specific siRNA 16 hr post-
doxorubicin treatment. Red arrow indicates loss of the G1 peak in p27Kip1-depleted cells.
(C) Quantification of the percentage of G1-arrested cells from 3 independent experiments performed as in (B). Error bars represent mean ± SEM, ***p < 0.001.
(D and E) Example of a typical EdU labeling experiment is shown in (D). In (E), loss of p27Kip1 causes entry into S-phase despite the presence of DNA damage in a
manner and magnitude comparable to that of hnRNPA0 knockdown. Quantified EdU incorporation assays were performed in H1299 cells transfected with a
p27Kip1-specific siRNA or transduced with a p27Kip1 or hnRNPA0-specific shRNA retrovirus, at 15-16 hr following application of 1 mM doxorubicin. EdU incor-
poration values were normalized to those of control undamaged cells treated with vehicle alone (Figures S2B and S2C). Bars represent mean percentage of
positive cells relative to vehicle-treated cells (see Figure S2B) ± SEM, n = 3 experiments. *p < 0.05.
See also Figure S2.and S1E) suggest that hnRNPA0 protein binds directly to the
p27kip1 mRNA via the 30 UTR. Taken together, these observa-
tions suggest that the observed upregulation of p27Kip1 in
response to DNA damage occurs primarily at the post-transcrip-
tional level through increased mRNA stability mediated by
hnRNPA0.
p27Kip1 Controls the DNA Damage-Induced G1/S
Checkpoint in p53-Deficient Cells
p27Kip1 is a prototypical CDK inhibitor that binds and inhibits Cy-
clin A and E/CDK2 and Cyclin D/CDK4 complexes to promote
G1 arrest during entry into quiescence (Toyoshima and Hunter,
1994). However, a role for p27Kip1 in the establishment of the
G1 checkpoint in response to DNA damage has not been well
described. This potential role for p27Kip1 as a DNA damage-
induced G1/S checkpoint regulator would likely be particularly626 Cancer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc.important in cells with defects or mutations in the p53 pathway
because those cells lack the p21(Cip1)-dependent G1/S check-
point (see Figure 4E), and p27Kip1 and p21 perform largely over-
lapping functions. To test whether this MK2/hnRNPA0/p27Kip1
pathway that we have characterized was causally responsible
for loss of the G1/S checkpoint in p53-null MK2/hnRNPA0
depleted cells, we knocked down p27Kip1 using RNAi (Figure 2A)
and monitored the integrity of the G1/S checkpoint by flow cy-
tometry. In control RNAi-treated cells, a substantial fraction of
the population (15%–20%) remains arrested in G1 (Figures
2B, top right, and S2A, top middle) 16 hr after doxorubicin treat-
ment, but this G1 arrest was almost completely ablated upon
p27Kip1 knockdown (Figures 2B, bottom right, and S2A, bottom
middle). Quantification from three independent experiments re-
vealed a near complete loss of G1 cells in the p27Kip1 knockdown
condition (Figure 2C). We confirmed that the loss of the G1
population in p27Kip1-depleted cells was due to inappropriate
progression through the cell cycle, rather than G1-driven cell
death, using EdU (5-ethynyl-20-deoxyuridine) labeling, a thymi-
dine analog that is incorporated into DNA during active synthesis
in S-phase (Buck et al., 2008) (Figure 2D). As shown in Figure 2E,
DNA damage induced by1 mM doxorubicin resulted in a 90%
decrease in EdU incorporation when assayed within the 1 hr win-
dowbetween 15 and 16 hr after treatment, relative to undamaged
control cells (Figure 2E, black bars; see also Figure S2C) due to
implementationofG1/Sand intra-Sphasecheckpoints.However,
depletion of p27Kip1 with either an siRNA or an shRNA targeting
distinct sequences in the p27Kip1 mRNA, resulted in a greater
than 2-fold increase in EdU incorporation at this time point after
damage (Figure 2E, red bars; see also Figure S2C), suggesting
that p27Kip1-depleted cells had indeed entered into S-phase
due to lossof theG1/Scheckpoint (Figure2B). Importantly, deple-
tionofp27Kip1hadnosignificant effectonEdU incorporation in the
absence of DNA damage (Figure S2B). Furthermore, the magni-
tude of enhanced EdU incorporation following p27Kip1 knock-
down mirrored that seen with hnRNPA0 knockdown (Figure 2E,
white bars; see also Figure S2C), indicating that p27Kip1 is thema-
jor hnRNPA0-target mRNA controlling the G1/S checkpoint.
MK2-Mediated Phosphorylation of hnRNPA0 in
Response to DNA Damage Induces Binding to Its Target
RNAs
Because MK2 is an important upstream regulator of hnRNPA0
function through phosphorylation of a single residue, serine 84
(Figure 3A) (Reinhardt et al., 2010; Rousseau et al., 2002), we
next examined the role of MK2 on induction of p27Kip1 mRNA.
As shown in Figures 3B and 3C, depletion of MK2 by RNAi pre-
vented both the DNAdamage-induced phosphorylation of serine
84 of hnRNPA0 (Figure 3B) and completely ablated p27Kip1
mRNA induction following doxorubicin treatment (Figure 3C).
This finding that p27Kip1 mRNA is induced in an MK2 and
hnRNPA0-dependent manner suggests a direct interaction be-
tween hnRNPA0 protein and p27Kip1 mRNA (Figures S1D and
S1E) that can be modulated by phosphorylation of hnRNPA0
by MK2. To test this, we performed an RNA immuno-precipita-
tion experiment using H1299 cell lines stably expressing HA-
tagged WT hnRNPA0 (HA-hnRNPA0-WT), or a mutant version
in which theMK2 phosphorylation site wasmutated to an alanine
(HA-hnRNPA0-S84A) (Figure S3A). As shown in Figure 3D, doxo-
rubicin-induced DNA damage led to an 8-fold increase in the as-
sociation of p27Kip1 mRNA with HA-hnRNPA0-WT and a 14-fold
increase in the association of Gadd45a mRNA (Figure 3D). In
contrast, mutation of the MK2 phosphorylation site in hnRNPA0
(Figure 3D, right-most bars) completely eliminated these DNA
damage-induced associations. Together with the previous
in vitro binding experiments (Figures S1D and S1E), these data
indicate that p27Kip1 mRNA is stabilized in response to DNA
damage through a direct interaction with hnRNPA0 in an MK2-
regulated manner.
MK2 Phosphorylation of hnRNPA0 Promotes Its
Cytoplasmic Accumulation in Response to DNA Damage
MK2 phosphorylation of serine 84 of hnRNPA0 is clearly impor-
tant for its interaction with its target mRNAs p27Kip1 and
Gadd45a (Figure 3D) (Reinhardt et al., 2010), but the molecularCabasis has remained elusive. Other members of the hnRNP family
of RNA binding proteins shuttle between the nucleus and the
cytoplasm under steady-state conditions, but in response to
certain extracellular stimuli they can be preferentially retained
in one of the two subcellular compartments (Shyu and Wilkin-
son, 2000). To determine whether hnRNPA0 sub-cellular locali-
zation was altered by DNA damage, we subjected H1299
cell lines stably expressing HA-hnRNPA0-WT or HA-hnRNPA0-
S84A, to doxorubicin treatment, and examined their localiza-
tion by subcellular fractionation and by immunofluorescence
microscopy of intact cells. In undamaged cells, hnRNPA0 was
predominantly nuclear, as assessed by western blotting of frac-
tionated lysates for the HA-tagged protein, lamin A (a nuclear
marker) and g-tubulin (a cytoplasmic marker) (Figure 3E,
compare lanes 1 and 3). This was further confirmed by immuo-
fluoresence in whole cells using antibodies against the HA tag
(Figure 3F, top row). Doxorubicin-induced DNA damage led to
a decrease in the nuclear fraction of hnRNPA0 (Figure 3E,
compare lanes 1 and 2) with a concomitant increase in its cyto-
plasmic abundance (Figure 3E, compare lanes 3 and 4). This was
further substantiated by whole cell imaging (Figure 3F, second
row, and Figure 3G), indicating that DNA damage induces the
cytoplasmic re-localization of hnRNPA0. Strikingly, the non-
phosphorylatable HA-hnRNPA0-S84A mutant displayed a
similar nuclear-cytoplasmic distribution to HA-hnRNPA0-WT in
the basal undamaged state (Figure 3E, lanes 5 and 7), but its
localization was entirely unaltered by doxorubicin treatment (Fig-
ure 3E, compare lanes 5 and 6; Figures 3F, rows 3 and 4, and
3G). Quantification of the imaging data from multiple experi-
ments revealed an 30% increase in cells with predominantly
cytoplasmic HA-hnRNPA0-WT upon doxorubicin treatment
that was not observed in the cells expressing the HA-
hnRNPA0-S84A phospho-defective form (Figure 3G). Taken
together, these biochemical and image-based data indicate
that MK2-mediated phosphorylation of hnRNPA0 leads to an in-
crease in its cytoplasmic localization in response to DNA dam-
age where it is well positioned to bind to and stabilize its target
mRNAs p27Kip1 and Gadd45a.
Synthetic Lethality between hnRNPA0 Loss and a
Defective p53 Pathway in Response to Chemotherapy
Since loss of hnRNPA0 abrogates both the G1 checkpoint
through p27Kip1 (Figures 1 and 2) and the G2/M checkpoint
through Gadd45a (Reinhardt et al., 2010), thereby reducing the
time for DNA repair prior to the next cell cycle transition, we hy-
pothesized that hnRNPA0-depleted cells would be sensitized to
killing by DNA-damaging chemotherapy. To test this, cell death
was assayed by measuring cleaved caspase 3 in control or
hnRNPA0-depleted H1299 cells in response to doxorubicin-
induced DNA damage. As shown in Figure 4A, knockdown of
hnRNPA0 in human p53-deficient/null H1299 cells resulted in
2-fold more cell death in response to low-dose doxorubicin as
compared to control RNAi-treated cells (Figure 4A, black versus
white +Dox bars). The effect of hnRNPA0 depletion on cisplatin-
induced cell killing was even more pronounced, resulting in a
4-fold increase in death compared to the control vehicle-treated
cells (Figure 4B; black versus white +Cis bars). Furthermore, we
could recapitulate these findings from human NSCLC cells with
two independent shRNAs in a genetically defined murine cell linencer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc. 627
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Figure 3. MK2-Mediated Phosphorylation of hnRNPA0 in Response to DNA Damage Induces Binding to Its Target RNAs and Cytoplasmic
Localization
(A) Schematic representation of hnRNPA0 domain architecture and sequence surrounding Serine-84 in the linker region between the two RNA recognition motifs
(RRMs). The MK2 phosphorylated residue, serine-84, is highlighted in red.
(B) Western blots of H1299 cells transduced with a control shRNA or an MK2-specific shRNA and treated with vehicle or doxorubicin.
(C) qRT-PCR analysis of cells treated as in (B).
(D) Stable H1299 cell lines harboring HA-tagged WT hnRNPA0 or a Ser-84-to-Ala mutant were treated with doxorubicin for 16 hr followed by HA-immuno-
precipitation. Co-precipitated RNA was subjected to qRT-PCR for p27Kip1 and Gadd45a mRNAs. Data shown as fold-change versus the WT untreated control.
Error bars represent mean ± SEM, n = 2 independent experiments.
(E) Nuclear-cytoplasmic fractionation of H1299 cells following 16 hr doxorubicin treatment.
(F) Immuno-flourescence microscopy of H1299 cells fixed 16 hr after 2 mM doxorubicin treatment. Scale bar represents 5 mm.
(G) Quantification of hnRNPA0 localization immuno-flourescence from two independent experiments, error bars represent mean ± SEM.
See also Figure S3.KP7B (Figures 4C and S4A) (Doles et al., 2010) derived from a K-
RasG12D;p53/ NSCLC tumor model (Jackson et al., 2005). We
further confirmed that our acute measure of cell death in
response to DNA-damaging chemotherapy reflected long-term
survival of these cells using both colony formation assays (Fig-
ure S4B) and fluorescence-labeling based competition assays628 Cancer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc.(Figures S4C and S4D). These data indicate that loss of
hnRNPA0 sensitizes p53-null cells to the cytotoxic effects of
chemotherapy.
Many human tumors are not entirely p53-deficient (i.e., null),
but instead have point mutations in critical ‘‘hotspot’’ regions
of this prominent tumor suppressor. To determine whether p53
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Figure 4. Synthetic Lethality between hnRNPA0 Loss and a Defective p53 Pathway in Response to Chemotherapy
(A and B) H1299 (p53-null) cells were transfected with a control or hnRNPA0-specific siRNA and treated with doxorubicin or cisplatin as indicated, followed by
western blotting for cleaved caspase 3. Data are represented as fold-change versus control siRNA vehicle-treated cells. Error bars represent mean ± SEM, n = 3
experiments. *p < 0.05 **p < 0.01 ***p < 0.001.
(C) K-RasG12D;p53/ KP7Bmurine lung adenocarcinoma cells were transduced with a miR-30 retrovirus expressing an hnRNPA0-specifc shRNA and treated as
indicated.
(D) A panel of p53-mutant and -WT cell lines were transduced or transfected with hnRNPA0-targeting shRNA or siRNA and cell death in response to cisplatin
assayed by measuring cleaved caspase 3. Shown is fold change in cell death in cisplatin-treated hnRNPA0-knockdown cells relative to cisplatin-treated control
siRNA/shRNA cells. Bars represent mean ± SEM, n = 3-5. *p < 0.05.
(E) Heatmap representation of Log2 fold change in the mRNA levels of the indicated p53-target genes after 16 hr of 10 mM cisplatin treatment. Lower image is a
p53 western blot of the indicated cell lines treated or not with 10 mM cisplatin for 16 hr.
(F) p53 levels from untreated cells from (E) were normalized to beta-actin, Log2 transformed, and plotted against the Log2 transformed data from (D). The linear
regression and the Pearson R2 are shown.
(G) p53-WT H1944 cells were transfected with the indicated siRNAs for 48 hr followed by treatment with 10 mM cisplatin for 24 hr and measurement of cleaved
caspase 3. Bars represent mean ± SEM, n = 3. *p < 0.05.
See also Figure S4.status was an important biomarker of chemo-sensitization medi-
ated by hnRNPA0 loss, we knocked down hnRNPA0 by RNAi in a
panel of p53-mutant and p53-WT NSCLC cell lines, treated them
with cisplatin, and assayed cell death (Figures 4D and S4F–S4H).
As shown in Figure 4D hnRNPA0 knockdown enhanced
cisplatin-induced cell death in all p53-mutant cell lines to varying
degrees, with H2009 and H1734 cells being the most responsive
(Figure 4D first two bars). Both of these cell lines express a ho-Camozygous p53R273L mutant protein, the most common p53 mu-
tation found in NSCLC, accounting for >5% of all p53mutations
(http://p53.free.fr/Database/p53_cancer/p53_Lung.html). Anal-
ysis of p53 target gene expression by qRT-PCR confirmed a
largely abrogated p53 response in the p53-mutant cell lines
(Figure 4E).
P53 mutations that functionally disable the WT protein often
lead to stabilization of p53 proteins due to loss of a p53-drivenncer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc. 629
MDM2-mediated negative feedback (Olive et al., 2004). Indeed
our p53-mutant cell lines were characterized by high basal levels
of p53 that were not further stabilized upon DNA damage (Fig-
ure 4E), in marked contrast to the WT cell lines that expressed
low basal levels of p53 that was substantially induced upon
DNA damage (Figure 4E). Because not all p53mutations disable
p53 function equivalently, it has been proposed that higher p53
protein expression can be used as a surrogate marker for
more disabling p53 mutations (Tsao et al., 2007; Yemelyanova
et al., 2011). Interestingly, we observed that basal p53 levels
(as measured in Figure 4E) were highly correlated with the extent
to which hnRNPA0-loss induced chemo-sensitization in our
cell line panel (Figure 4F, R2 = 0.8903, p = 0.016), suggesting
that p53 expression might serve as a generalizable biomarker
for the extent to which cells are dependent upon the hnRNPA0
pathway for survival following treatment with DNA-damaging
chemotherapy.
Clearly, both p53-null and -mutant cells are sensitized to DNA-
damaging chemotherapy whereas p53-WT cells appear be unaf-
fected by hnRNPA0 loss. To distinguish whether this synthetic
lethal interaction between p53 loss of function and hnRNPA0
depletion was due to chronic adaptive changes in cells with
abrogated p53 responses, or an acute effect of p53 loss of func-
tion, we then performed combination hnRNPA0/p53 knockdown
experiments in p53-WT H1944 cells (Figure 4G). Depletion of
hnRNPA0 alone had no demonstrable effect on cisplatin-
induced cell death in this p53-proficient cell line (Figure 4G,
compare second and fourth white bars). As expected, p53
knockdown completely abrogated cisplatin-induced cell death
(Figure 4G, compare second white bar and second blue bar).
Strikingly, combined knockdown of hnRNPA0 on a background
of p53 depletion re-sensitized these cells to cisplatin-induced
cell death (Figures 4G, compare second and fourth blue bars,
and S4H). Similar results were obtained with doxorubicin treat-
ment in A549 cells, a second p53-WT cell line, upon single and
combined hnRNPA0/p53 knock-down (Figure S4I). These data
suggest that targeting of hnRNPA0 can sensitize cells that
have acutely lost p53 function to DNA-damaging chemotherapy.
To address the importance of MK2 phosphorylation of
hnRNPA0 in mediating cisplatin resistance, we performed
knockdown-rescue experiments with WT and mutant hnRNPA0
in KP7B cells (Figure S4J). Endogenous hnRNPA0was knocked-
down with a retroviral shRNA targeting the 30 UTR followed by
reconstitution with either HA-hnRNPA0-WT or HA-hnRNPA0-
S84A cDNA of human origin (Figure S4J, upper image; note
mobility shift due to the 23 HA-tag). These cells were then
treated with cisplatin and assayed for cell death (Figure S4J,
middle). Knockdown of hnRNPA0 increased cell death in
response to cisplatin (Figure S4J, bottom; compare second
black bar and second white bar), whereas re-expression of
HA-hnRNPA0-WT completely abrogated this effect (Figure S4J,
bottom; compare second white bar to fourth white bar). In stark
contrast, re-expression of HA-hnRNPA0-S84A failed to rescue
the hnRNPA0 knockdown phenotype (Figure S4J, bottom;
compare second white bar and sixth white bar). These data sug-
gest that phosphorylation of hnRNPA0 is not only required for its
interaction with targetmRNAs, but also required for cells to resist
killing by chemotherapy, potentially due to a requirement for
damage-induced hnRNPA0 cytoplasmic localization (Figure 3).630 Cancer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc.Reduced hnRNPA0 Activity Promotes Cisplatin Efficacy
In Vivo in a Murine p53-Deficient NSCLC Model
To determine whether hnRNPA0 promotes resistance of estab-
lished lung tumors to cisplatin-based chemotherapy in vivo, we
took advantage of a transplantable model of NSCLC (Doles
et al., 2010; Morandell et al., 2013). In this model, KP7B cells
are transplanted in syngeneic, immune-competent recipient
mice (Figure 5A) (Doles et al., 2010). The advantages of this
model over a traditional xenograft approach are 3-fold: First, tu-
mors arising in recipient mice are pathologically and molecularly
indistinguishable from the tumors from which they were derived
(Doles et al., 2010), which are themselves strikingly similar to
their human counterparts (Jackson et al., 2005; Sweet-Cordero
et al., 2004). Second, the cells give rise to tumors in the correct
anatomical location in the presence of a fully functional host im-
mune system. Lastly, and most importantly for our studies, this
model is highly tractable and allows genetic manipulation of pro-
teins of interest prior to transplantation.
We generated stable KP7B cell lines by introduction of an
hnRNPA0-specific shRNA that efficiently knocked down its in-
tended target (Figure S5A), along with a retrovirus expressing
luciferase to facilitate imaging of response to therapy (Figure 5A).
These cell lines were then transplanted into multiple syngeneic
recipient mice, and tumors were allowed to form until strong
bioluminescence was observed in the lungs of all animals
(16 days post-transplantation) to assess therapeutic response
in established tumors. Although no significant difference in biolu-
minescence was observed between control and hnRNPA0-
depleted tumors in the absence of DNA-damaging chemo-
therapy (Figures 5B and 5C; Figure S5B, pre-treatment
condition), upon treatment with cisplatin, control tumors
continued to grow rapidly but growth of hnRNPA0-depleted tu-
mors was markedly suppressed (Figures 5B and 5C). MicroCT
imaging of a second cohort of animals treated with a single
high dose of cisplatin (10 mg/kg) confirmed the superior
response of hnRNPA0-depleted tumors to chemotherapy (Fig-
ures S5B–S5D). Consistent with the short term tumor response
data, mice transplanted with hnRNPA0-proficient cells obtained
no significant survival benefit from cisplatin treatment (Figure 5D,
compare red and blue lines, p = 0.52) indicating that tumors in
this model are entirely recalcitrant to cisplatin-based chemo-
therapy (Doles et al., 2010). In contrast, animals transplanted
with hnRNPA0-depleted tumors displayed a significant survival
benefit upon cisplatin treatment (Figure 5E, compare red and
blue lines, p < 0.0001) indicating that the acute tumor growth ef-
fect we observed in response to therapy (Figures 5B and 5C)
directly translated into an extension of lifespan in this murine
NSCLC model (Figures 5D and 5E). Taken together, these data
indicate that the presence of hnRNPA0 promotes resistance of
established lung tumors to cisplatin-based chemotherapy
in vivo.
hnRNPA0 Promotes Resistance to Chemotherapy
through Stabilization of p27Kip1 and Gadd45amRNAs
Our data demonstrate that in response to DNA-damaging
chemotherapy, MK2-mediated phosphorylation of hnRNPA0
stabilizes the mRNAs of p27Kip1 and Gadd45a to control the
G1/S and G2/M checkpoints, respectively (Figure 6A). However,
the relative contributions provided by either of these two target
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Figure 5. Decreased hnRNPA0 Activity Promotes Cisplatin Efficacy against p53-Defective NSCLC In Vivo
(A) Schematic representation of the transplantable NSCLC model.
(B) Representative bio-luminescence images before and after cisplatin treatment on Days 0 and 7. Red arrows indicate timing of cisplatin dosing.
(C) Quantification of lung bio-luminecence pre-treatment and 5 days post-cisplatin treatment. Error bars represent mean ± SEM, three to four animals per
condition, *p < 0.05.
(D) Post-treatment Kaplan-Meier survival analysis of control tumor-bearingmice with or without cisplatin treatment, as indicated. (Vector n = 7, vector +Cis n = 7).
(E) Post-treatment Kaplan-Meier survival analysis of shA0 tumor-bearingmice with or without cisplatin treatment, as indicated. (shA0(3) n = 7, shA0(3) +Cis n = 9).
p values in (D) and (E) were calculated using the log-rank test.
See also Figure S5.mRNAs to the overall enhanced chemosensitivity of hnRNPA0
knockdown cells/tumors (Figures 4 and 5) are unknown. To
determine this, we depleted p53-null H1299 cells of either
p27Kip1 alone, Gadd45a alone, or both RNAs simultaneously.
The isolated or combined knockdown of p27Kip1 and Gadd45a
had no significant effect on untreated cells, indicating that loss
of these two proteins is not acutely toxic to cells in the absence
of DNA damage (Figures 6B, S6A, and S6B). Knockdown of
either of these hnRNPA0-target mRNAs individually had no ef-
fect on cell death in response to cisplatin (Figure 6B, red and
blue bars compared to the black bars) or doxorubicin (Fig-
ure S6B). Strikingly, however, co-depletion of both hnRNPA0-
target mRNAs resulted in a markedly enhanced amount of cell
death, and fully recapitulated the effect of hnRNPA0 knockdownCaon response to cisplatin (Figure 6B, compare white bars and pur-
ple bars) and doxorubicin (Figure S6B). Taken together, these
data indicate that MK2/hnRNPA0 promotes the resistance of
p53-defective cells to chemotherapy by the combined action
of stabilizing both p27Kip1 and Gadd45a mRNAs to control the
G1/S and G2/M checkpoints, respectively.
Reduced Levels of hnRNPA0-Target mRNAs Correlate
with Favorable Response to Adjuvant Chemotherapy in
Patients with NSCLC
The observation that the MK2/hnRNPA0 pathway promotes
resistance to chemotherapy in NSCLCmodels through the coor-
dinate post-transcriptional control of the p27Kip1 and Gad-
d45a-regulated DNA damage G1/S and G2/M checkpointsncer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc. 631
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Figure 6. hnRNPA0 Promotes Resistance to Chemotherapy through p27Kip1 and Gadd45a
(A) Model depicting the role of MK2, hnRNPA0, p27Kip1, and Gadd45a in the DNA damage response, limiting the efficacy of anti-cancer chemotherapy.
(B) H1299 (p53-null) cells were transfected with the indicated siRNAs and analyzed as in Figure 4. Error bars represent mean ± SEM, n = 3 experiments. **p < 0.01,
***p < 0.001, n.s. = not significant. Control siRNA and A0 siRNA data from Figure 4B are shown again here for comparison.
(C and D) Patients with stage 2 disease from the JBR.10 lung cancer adjuvant chemotherapy trial were clustered into two groups based on expression of both
p27Kip1 and Gadd45a. Patients in this trial were either observed (Obs, orange line) or treated with cisplatin/vinorelbine-based chemotherapy (Chemo, green line).
Kaplan-Meier analysis based on expression of MK2/hnRNPA0-target mRNAs demonstrates that only those patients with low levels of these mRNAs benefit
significantly from adjuvant chemotherapy. The p values were calculated using the log-rank test.
See also Figure S6.suggests that human tumors with low levels of activity through
this pathway, either by means of natural heterogeneity or phar-
macological intervention, might be more likely to respond to
cisplatin-based chemotherapy. To test this, we made use of
data from the NCIC CTG JBR10 clinical trial in which patients
with stage 1B or 2 NSCLC underwent surgical resection and
were then either observed or given cisplatin/vinorelbine adjuvant
chemotherapy (Winton et al., 2005). This dataset was selected
for analysis for several reasons. First, banked snap-frozen tu-
mors from a subset of patients were subjected to gene expres-
sion profiling prior to therapy, thus facilitating identification of
genetic determinants of therapeutic response (Zhu et al.,
2010). Second, this trial had a control/observation arm thus al-
lowing for factors that regulate response to therapy (predictive
markers) to be differentiated from those that affect tumor growth
per se (prognostic markers). Unsupervised clustering on p27Kip1
and Gadd45a expression was used as a surrogate for assessing
activity through the MK2/hnRNPA0 pathway and two distinctive
clusters were identified (Figure S6C): one cluster with high
expression of p27Kip1 and Gadd45a and the other with low
expression. We focused our analysis on patients with stage 2
NSCLC (Table 1) because adjuvant chemotherapy has been632 Cancer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc.shown to be beneficial mainly in this subset of patients with early
stage disease (Winton et al., 2005). As shown in Figure 6C, pa-
tients with high expression of p27Kip1 and Gadd45a did not
benefit from adjuvant chemotherapy (Figure 6C, compare or-
ange and green lines, HR 1.48, 95% CI 0.47–4.67, p = 0.502).
Whereas, patients with low levels of these hnRNPA0-target
mRNAs received significant benefit from adjuvant chemo-
therapy (Figure 6D, compare orange and green lines, HR 0.23
95% CI 0.07–0.71 p = 0.011). Importantly, patients in the obser-
vation arm of the trial whose tumors express low levels of
p27Kip1 and Gadd45a appeared to show the poorest survival
of all groups analyzed (Figure 6D, orange line) similar to mice
harboring hnRNPA0-depleted tumors (Figures 5D and 5E,
compare blue line in 5D to the blue line in 5E; p = 0.0023). More-
over, only consideration of both p27kip1 and Gadd45a expres-
sion together, but neither alone, had a significant association
with therapeutic response (Figure S6D). Because our data
from a panel of NSCLC cell lines indicated that high basal p53
protein levels correlated with superior response to hnRNPA0
knockdown-induced chemosensitization (Figures 4D–4F), we
further stratified patients based upon p53 immuno-histochemis-
try status: p53 IHC positive/putatively mutant and p53 IHC
Table 1. Association of p27kip1/Gadd45aExpressionwith Clinical
Factors in Stage 2 NSCLC
Parameter
Expression of p27 and GADD45a
High (%, n = 30) Low (%, n = 30) p Value
Histology ADC 16 (55.2) 13 (44.8) 0.725
SQCC 12 (44.4) 15 (55.6)
LCUC 2 (50.0) 2 (50.0)
Chemotherapy OBS 18 (64.3) 10 (35.7) 0.038
ACT 12 (37.5) 20 (62.5)
Age (yr) <65 26 (49.1) 27 (50.9) 0.688
R65 4 (57.1) 3 (42.9)
Sex male 24 (53.3) 21 (46.7) 0.371
female 6 (40.0) 9 (60.0)
P53 IHCa negative 11 (44.0) 14 (56.0) 0.571
positive 14 (51.9) 13 (48.1)
unknown 5 (62.5) 3 (37.5)
aNegative is used as a surrogate of wild type p53, positive as a surrogate
of p53 with missense mutation.negative/putatively WT (Tsao et al., 2007). Although the number
of patients is very small, the data suggest that patients whose
tumors express low levels of p27Kip1 and Gadd45a, and addi-
tionally have stabilizing p53 mutations, benefit most from adju-
vant cisplatin-based chemotherapy (Figures S6E and S6F).
Taken together, these murine (Figure 5) and human clinical
data (Figures 6 and S6) indicate that hnRNPA0 promotes resis-
tance to chemotherapy in p53-mutant NSCLC through p27Kip1
and Gadd45a (Figure 6A).
Mutual Exclusivity of the p53 and MK2/hnRNPA0
Pathways Is Ensured by p53/p21-Mediated Suppression
of hnRNPA0
To ascertain the molecular basis for the p53 context-depen-
dence of hnRNPA0 for DNA damage tolerance, we next investi-
gatedwhether there is a regulatory relationship between p53 and
hnRNPA0. We noted that when p53-proficient cells were treated
with doxorubicin, a marked suppression of hnRNPA0 protein
levels was observed (Figure 7A, compare lanes 1 and 2 and first
two black bars), that was not seen in p53-null cells (see Fig-
ure 1E). To examine whether this reduction in hnRNPA0 required
p53, we knocked down p53 with siRNA, treated the cells with
doxorubicin, and measured hnRNPA0 protein levels. The pro-
nounced decrease in hnRNPA0 following DNA damage that we
observed previously was largely ablated upon p53 knockdown
(Figure 7A) suggesting that p53 or its downstream effectors
actively suppresses hnRNPA0. Conversely, activation of p53
even in the absence of DNA damage was sufficient to suppress
hnRNPA0. In these experiments treatment of A549 cells with the
MDM2 inhibitor Nultin 3a to upregulate p53 resulted in downre-
gulation of hnRNPA0 protein and mRNA in control siRNA-trans-
fected cells (Figure 7B, left and right lower images, black bars),
but not in p53-depleted cells (Figure 7B, red bars). These
findings suggest that the drop in hnRNPA0 protein levels is likely
a consequence of decreased mRNA levels, either due to
decreased transcription, or to post-transcriptional destabiliza-
tion of the hnRNPA0 mRNA.CaBecause many RNA-binding proteins are auto-regulated or
regulated by other RNA-BPs at the post-transcriptional level,
and the hnRNPA0 30 UTR is long and highly conserved (Fig-
ure S7A), we first examined whether hnRNPA0 mRNA was de-
stabilized upon p53 activation. To test this, we measured
hnRNPA0 mRNA stability in Nutlin 3a-treated cells in the same
manner as we had assessed p27kip1 mRNA stability in response
to doxorubicin (Figure 1G). As shown in Figure 7C, the half-life of
hnRNPA0 mRNA dropped from16 hr in vehicle-treated cells to
6 hr following p53 activation with Nutlin 3a. Moreover, half-life
estimates averaged from multiple experiments revealed an
50% decrease in hnRNPA0mRNA half-life upon p53 activation
(Figure 7D), closely mirroring the drop seen in total hnRNPA0
mRNA levels (Figure 7B, right, black bars). Because p21 is the
primary effector of p53-mediated G1/S checkpoint control, we
next asked whether suppression of the hnRNPA0 successor
pathway was p21-dependent. We knocked down p21 using
siRNA in A549 cells, treated them with Nutlin 3a to activate
p53 (Figure 7E, left) and measured hnRNPA0 protein and
mRNA levels. Indeed, the repression of hnRNPA0 mRNA (Fig-
ure 7E, right) and hnRNPA0 protein (Figure S7B) was largely ab-
lated by depletion of p21. Although the precise molecular basis
for this p21-dependent hnRNPA0 mRNA destabilization remains
to be determined, these findings clearly point to an important role
for p21 induction in suppression of hnRNPA0 expression. These
data suggest that rather than functioning in parallel pathways,
the primary p53/p21 and the successor MK2/hnRNPA0 path-
ways of cell cycle checkpoint control are mutually exclusive,
and that this is ensured by suppression of the successor
pathway at the level of hnRNPA0 mRNA destabilization
(Figure 7F).
DISCUSSION
Post-transcriptional control of gene expression is becoming
increasingly appreciated as a target of the DDR. Several unbi-
ased screens have implicated RNA binding proteins (RNA-BPs)
as one of the most enriched classes of genes involved in acti-
vating and modulating the DDR (Beli et al., 2012; Matsuoka
et al., 2007; Paulsen et al., 2009; Reinhardt et al., 2010). To
date, however, there are few examples of RNA-BPs that have
been implicated as functionally important in the execution of
specific cellular decisions in response to DNA damage, or had
their relevant target RNAs interrogated in this regard (Abdelmoh-
sen et al., 2007). Here we have shown that the RNA-BP
hnRNPA0 is a major substrate of the checkpoint kinase MK2,
and that it enforces cell cycle arrest and promotes resistance
to DNA-damaging chemotherapy through two distinct target
mRNAs that respectively control the G1/S and G2/M DNA dam-
age checkpoints in cultured cells and in vivo. These findings
indicate that in addition to modulating the DDR itself, RNA-BPs
are intimately involved in critical life and death decisions.
More broadly, recent advances in the high-throughput identifica-
tion of RNA-protein interactions, such as high throughput
sequencing crosslink immunoprecipitation (HITS-CLIP) (Darnell,
2010), should help to elucidate the role of other RNA-BPs iden-
tified in recent screening approaches and may shed light on
the breadth and extent of post-transcriptional control of gene
expression in the context of the DDR.ncer Cell 28, 623–637, November 9, 2015 ª2015 Elsevier Inc. 633
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Figure 7. The Primary p53/p21 Axis Actively Suppresses the Successor hnRNPA0 Pathway
(A) p53-WT A549 cells were transfected with a control siRNA or a p53-targeting siRNA for 48 hr, followed by treatment with 2 mM doxorubicin for 24 hr. hnRNPA0
protein expression wasmeasured bywestern blotting. Data are plotted as fold-change in hnRNPA0 protein (normalized to actin) relative to vehicle-treated control
siRNA transfected cells, bars represent mean ± SEM, n = 3 experiments. **p < 0.01.
(B) p53-WT A549 cells were transfected with siRNAs as in (A), then treated with 10 mMMDM-2 inhibitor/p53 activator Nutlin 3a for 24 hr. Left: data are plotted as
fold-change in hnRNPA0 protein (normalized to actin) relative to vehicle-treated control siRNA transfected cells, bars represent mean ± SEM, n = 4 experiments.
*p < 0.05. Right: data are plotted as fold-change in hnRNPA0mRNA relative to vehicle-treated control siRNA transfected cells, bars represent mean ± SEM, n = 3
experiments. **p < 0.01.
(C) A549 cells were treated as in (B) except that at 24 hr actinomycin Dwas added to the culturemedium and time points taken for RNA analysis by qRT-PCR. Data
represent percent remaining hnRNPA0 mRNA for each condition relative to the 24 hr time point where actinomycin was added.
(legend continued on next page)
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Our work demonstrates that hnRNPA0 regulates p27kip1
expression in a context-specific manner in response to DNA-
damaging chemotherapy and complements a growing body of
literature documenting the critical contribution of post-transcrip-
tional control by multiple regulators (e.g., miR-221, DND1 and
Pumillio) to p27kip1 expression (Kedde et al., 2007, 2010). The
binding of hnRNPA0 to p27kip1 mRNA appears to occur via the
30 UTR but in a region that is distinct from that of miR-221,
DND1 or Pumillio (Kedde et al., 2007, 2010). Together these
data indicate that the p27kip1 30 UTR acts as a platform for
different post-transcriptional regulators dependent upon the
extracellular cues (e.g., growth factors, DNA damage, etc.) and
genetic context (e.g., p53 mutation) in which a specific cell
exists.
MK2 activation of cell cycle checkpoints in p53-compromised
cells promotes resistance to doxorubicin or cisplatin-based
chemotherapy, raising the possibility that targeting this pathway
in human tumors may preferentially kill p53-mutant tumor cells
while sparing p53-WT normal cells (Morandell et al., 2013; Rein-
hardt et al., 2007). MK2 controls the G2/M checkpoint by regu-
lating the activity of the RNA-BP hnRNPA0 and causing stabiliza-
tion of Gadd45a mRNA (Reinhardt et al., 2010). Here we have
shown that, in addition to regulation of the G2/M checkpoint,
hnRNPA0 also enforces a G1/S checkpoint through stabilization
of p27Kip1 mRNA. Traditionally p27Kip1 is regarded as the major
CDK inhibitor that induces G1 arrest upon contact inhibition or
during terminal differentiation (Hsieh et al., 2000; Polyak et al.,
1994) but a role for p27Kip1 in control of the DNA damage check-
points has largely been overlooked with two notable exceptions
(Cuadrado et al., 2009; Liontos et al., 2010). Our data clearly
implicate p27Kip1 as the major controller of the G1/S checkpoint
following DNA damage in p53-null cells. Interestingly, a previous
report implicated p27Kip1 in long-term maintenance of cell cycle
arrest in p53-WT A549 cells after long-term exposure to doxoru-
bicin (Cuadrado et al., 2009). In that study p27Kip1 was only
important for controlling the G1/S checkpoint once the initial
wave of p53-p21 activity had diminished (Cuadrado et al.,
2009). In agreement with these observations, we show that in
those same p53-WT A549 cells acute (24 hr), activation of p53
by doxorubicin or MDM2 inhibition suffices to downregulate
hnRNPA0 in a p53/p21-dependent manner. These data support
a mutual exclusivity model where p27Kip1 control of the G1/S
checkpoint only becomes essential in cells that do not have an
active p53-p21 pathway and thus fail to suppress hnRNPA0 (Fig-
ure 7F). Interestingly, Gadd45a is a transcriptional target of p53
in response to DNA damage, but in p53-null cells is induced by
the MK2/hnRNPA0-dependent stabilization of its mRNA. There-
fore, Gadd45a control of the G2/M checkpoint is functionally
maintained in the absence of p53 by a switch from transcriptional
to post-transcriptional control (Figure 7F). Together these data
indicate that hnRNPA0 is the ‘‘successor’’ to p53 for checkpoint
control in response to DNA-damaging chemotherapy and that a(D) Slopes of the lines from three independent experiments performed as in (C) we
activation. Bars represent mean ± SEM.
(E) A549 cells were transfected with a control siRNA or a p21-targeting siRNA for
mRNA expression was measured by qRT-CPR. Data are plotted as fold-change
represent mean ± SEM, n = 3 experiments. *p < 0.05, **p < 0.01.
(F) Model representation of the interplay between the p53 and MK2/hnRNPA0 p
See also Figure S7.
Camechanistic switch from transcriptional control of p21 and
Gadd45a to post-transcriptional control of p27Kip1 and Gadd45a
enforces the G1/S and G2/M checkpoints and drives chemo-
resistance (Figure 7F).
Intrinsic drug resistance is a major obstacle to the successful
treatment of human malignancies. Some patients receive signif-
icant benefit from cytotoxic DNA-damaging chemotherapy but
identifying these patients a priori is a significant challenge (Kel-
land, 2007). Here, we have shown that p53-null/mutant NSCLCs
rely on anMK2/hnRNPA0/p27Kip1/Gadd45a pathway to promote
cell cycle arrest and resist killing by chemotherapy. In light of our
findings in tumor cell lines and animal models, we investigated
whether the status of this pathway correlated with therapeutic
response in patients with NSCLC. Consistent with our experi-
mental data, we observed that patients with stage 2 NSCLC
with low levels of hnRNPA0-target mRNAs received significant
benefit from adjuvant chemotherapy after surgical resection
that was exacerbated still further when analyzing patients with
p53-mutant tumors, whereas those with high levels of MK2/
hnRNPA0-target mRNAs did not. Although our findings in this
well-annotated small patient cohort will require independent
large scale verification, our data suggest that the use of
p27Kip1 and Gadd45a mRNA levels in combination with p53
IHC as predictive biomarkers could identify a subset of patients
at diagnosis who are most likely to benefit from platinum-based
chemotherapy. Our data therefore highlight a critically important
unifying role for the cytoplasmic MK2/hnRNPA0 p53-successor
pathway in dictating tumor response to therapy in NSCLC
through post-transcriptional control of two distinct cell cycle
checkpoints (Figure 7F).
EXPERIMENTAL PROCEDURES
RNA-IP and qRT-PCR
RNA-IPs were performed as described previously (Reinhardt et al., 2010) with
the addition of 4-thiouridine (4SU) labeling prior to drug treatment. Briefly,
H1299 cells expressing HA-hnRNPA0 were treated with 100 mM 4SU for
24 hr, followed by treatment with 2 mM doxorubicin for 16 hr. At the end of
doxorubicin treatment, cells were washed once in ice-cold PBS and cross-
linked at 365 nm as described (Hafner et al., 2010). Cells were then scraped
in ice-cold PBS and RNA-IP performed as described previously (Keene
et al., 2006; Reinhardt et al., 2010) using HA-agarose beads (Sigma-Aldrich).
For qRT-PCR analysis, RNA was extracted using TRIzol reagent (Ambion) ac-
cording to the manufacturer’s instructions and 1 mg of total RNA was used for
reverse transcription using the superscript III first-strand synthesis kit (Invitro-
gen) and oligo-dT priming as per the manufacturer’s instructions. For qPCR,
cDNA was amplified using SYBR green PCR mastermix (Applied Biosystems)
according to the manufacturer’s cycling conditions for 40 cycles on a Bio-Rad
C1000 Thermal Cycler. Data were analyzed using the delta-delta Ct method as
described previously (Cannell et al., 2010) and plotted as fold change versus
control.
Murine NSCLC Transplant Model
A total of 50,000 KP7B cells, labeled with GFP-luciferase, were trans-
planted into 10- to 12-week-old syngeneic C57BL6/Jx129-JAE malere calculated and used to determine the fold change inmRNA half-life upon p53
48 hr, followed by treatment with 10 mM Nutlin 3a for 24 hr. p21 and hnRNPA0
in mRNA levels relative to vehicle-treated control siRNA transfected cells, bars
athways in response to DNA-damaging chemotherapy.
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recipient mice 6 hr after 5 Gy whole-body irradiation as described previ-
ously (Doles et al., 2010). Tumors were allowed to form for approximately
2 weeks and tumor growth was measured by microCT imaging on a
eXplore CT120-whole mouse MicroCT (GE Healthcare) (45 mm resolution,
80 kV, with 450 mA current) as described previously (Doles et al., 2010)
or bio-luminescent imaging on a IVIS Spectrum-bioluminescent and fluores-
cent imaging system (Xenogen). For all imaging procedures, animals were
pre-anesthesized with isoflourane. For drug treatments, cisplatin was dis-
solved in saline and injected intraperitoneally at 10 mg/kg for single high-
dose treatment, or with 7 mg/kg once weekly for 3 weeks for low-dose
treatment. Mice were killed when they were moribund or when they had
lost 20% of their initial body weight, whichever occurred sooner, according
to MIT Committee on Animal Care guidelines. All mouse studies were
approved by the MIT Institutional Committee for Animal Care, and conduct-
ed in compliance with the Animal Welfare Act Regulations and other federal
statutes relating to animals and experiments involving animals and adheres
to the principles set forth in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996 (Institutional Animal Welfare
Assurance no. A-3125–01).
Retrospective Analysis of p27Kip1 and Gadd45a mRNA Expression
and Therapeutic Response in NSCLC
This study used human tissues from a snap-frozen lung tumor bank that was
established at the Princess Margaret Hospital and Toronto General Hospital
in 1996, after approval by the Research Ethics Board of the University Health
Network. Patients’ demographic and clinical follow-up information was also
obtained after Research Ethics Board approval for chart reviews. Expression
of p27Kip1 and Gadd45a mRNAs in 133 NSCLC samples were profiled by us-
ing Affymetrix U133A (Zhu et al., 2010) represented by probe set 209112_at
and 203725_at, respectively. Two clusters were identified based on the
expression of p27Kip1 and Gadd45a using hierarchal clustering (Sturn
et al., 2002). The two clusters were defined as low and high expressed
groups based on the expression of these two genes (Figure S6C). For sur-
vival analysis, lung cancer specific survival was used as the survival endpoint
and Cox proportional hazards regression (SAS v9.3, SAS Institute) was used
to estimate the hazard ratio and test the significance. A p value of less than
0.05 was considered as significant. IHC staining and scoring for p53 protein
on tissue microarray (TMA) was described in detail in (Tsao et al., 2007).
Briefly, 4 mm sections from TMA were mounted onto slides. DO7 antibody
for p53 (NovoCastra Laboratories) was diluted at 1:200 and applied to the
sample, which was microwave-heated for antigen retrieval. The dilution
was optimized a priori to ensure that there was no stain on normal tissue.
Staining intensity was qualitatively scored from 0 (absent) to 3 (strong),
and the percentage of tumor cells with nuclear staining was estimated.
A sample with more than 15% cells with intensity scored 1 and above was
defined as IHC positive.
Statistical Analysis
Unless otherwise, specified, all p values were calculated using a two-tailed
Student’s t test in Graphpad Prism.
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